Skip to content
The Policy VaultThe Policy Vault

Evoxac (cevimeline)Highmark

Dry mouth in patients with Sjögren’s Syndrome

Preferred products

  • generic pilocarpine
  • generic cevimeline

Initial criteria

  • The member has a diagnosis of Sjögren’s Syndrome (Sicca Syndrome) (ICD-10: M35.0)
  • The member is experiencing symptoms of dry mouth
  • If the request is for brand Evoxac, the member meets all of the following (a and b):
  • a. The member has experienced therapeutic failure or intolerance to generic cevimeline
  • b. The member has experienced therapeutic failure, intolerance, or contraindication to the plan-preferred generic pilocarpine

Reauthorization criteria

  • The prescriber attests that the member has experienced positive clinical response to therapy
  • If the request is for brand Evoxac, the member has experienced therapeutic failure or intolerance to generic cevimeline

Approval duration

12 months